Homologous recombination deficiency predicted with the HRDetect tool corresponded to favorable breast cancer outcomes after platinum-based chemotherapy.
New studies suggest low-, intermediate-, and high-methylation subgroups exist in juvenile myelomonocytic leukemia, potentially offering insights into patient outcomes.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.
A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
An international team of researchers examined differential gene expression in blood samples from patients infected during the West African outbreak.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.